The office opening in Paris, France, gives PharmaLex the opportunity to extend its local reach in one of the key worldwide markets
As of 26 September, 2016, the PharmaLex Group, the leading specialist provider of development consulting, regulatory affairs and pharmacovigilance, has opened a new office in Paris, France.
With this office establishment, the PharmaLex Group is now able to provide its extensive service portfolio to French customers, ensuring local presence and cultural fit to its clients.
The new subsidiary will be co-led by Ms Sophie Guillaume, General Manager and Mr Patrick Larcier, PharmD, MBA, Senior Director, Drug Development and Vigilance. Together the two of them bring along more than 25 years of industry and consulting experience in building, structuring, growing and managing teams. Furthermore, Mr Larcier has profound global knowledge and expertise in regulatory matters, vital to the pharmaceutical industry.
'Together with Patrick Larcier, I am excited to have planted the seed for PharmaLex in France. We will grow our local presence in close co-operation with our international colleagues, allowing us to provide highest standards of quality of all services from the very beginning,' said Sophie Guillaume.
'For the pharmaceutical industry, France plays a significant role on an international level. It is of great importance and strategic interest to be able to service this highly thriving market,' highlights Dr Thomas Dobmeyer, one of the CEO’s of the PharmaLex Group.
His counterpart, Dr Tilo Netzer, added: 'With Patrick and Sophie, we are happy to welcome senior executives strengthening our international team. Patrick is a key expert for the design and implementation of consulting and regulatory services at all stages of clinical development for complex and innovative medicinal products.'
The PharmaLex Group now has more than 500 employees, with 19 offices in 13 countries and more than 550 satisfied clients worldwide.